Rheacell GmbH & Co. KG — Sponsor Intelligence | 3 EU Trials

Filter these 3 trials by condition, phase, country and more.

3 Registered trials

1 Recruiting

2 Completed trials

15 Countries active

16 Unique IMPs

100% Results reported

Phase III

Phase II

Oversight events:

1 serious breach 4 temporary halts across 2 trials

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

Top indications

3 total

Phase III clinical trial of ABCB5+ MSCs for the treatment of EB Recruiting

2022-500266-10-00 Phase III 12 countries ALLOGENEIC SKIN-DERIVED ABCB5-POSITIVE DERMAL MESENCHYMAL STROMAL CELLS; CETIRIZ…
CLINICAL STUDY TO TEST STEM CELLS FOR THE TREATMENT OF LONG-TERM, NON-HEALING VENOUS LEG ULCERS Ended

2024-512720-11-00 Phase III 10 countries ALLOGENEIC SKIN-DERIVED ABCB5-POSITIVE DERMAL MESENCHYMAL STROMAL CELLS
Study to investigate the efficacy and safety of allo-APZ2-CVU on wound healing of therapy-resistant chronic venous ulcer (CVU) Ended

2023-510162-27-00 Phase II 1 country ALLOGENEIC SKIN-DERIVED ABCB5-POSITIVE DERMAL MESENCHYMAL STROMAL CELLS

Showing 1–3 of 3 trials